Biology Reference
In-Depth Information
Kambayashi J, Shakur Y, Liu Y (2006) Bench to bedside: multiple actions of the PDE3 inhibitor
cilostazol. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases
in health and disease. CRC Press, Boca Raton, pp 627-648
Kang KK, Ahn GJ, Sohn YS, Ahn BO, Kim WB (2003) DA-8159, a new PDE5 inhibitor,
attenuates the development of compensatory right ventricular hypertrophy in a rat model of
pulmonary hypertension. J Int Med Res 31:517-528
Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardio-
vascular regulation. Circ Res 101:1084-1095
Ke H, Wang EH (2007a) Structure, catalytic mechanism, and inhibitor selectivity of cyclic nucleotide
phosphodiesterases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phospho-
diesterases in health and disease. Taylor & Francis Group, LLC, Boca Raton, pp 607-626
Ke H, Wang H (2007b) Crystal structures of phosphodiesterases and implications on substrate
specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403
Keravis T, Lugnier C (2010) Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr
Pharm Des 16(9):1114-1125
Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C (2001)
Upregulation of phosphodiesterase 1A1 expression is associated with the development of
nitrate tolerance. Circulation 104:2338-2343
Klabunde RE (1983) Dipyridamole inhibition of adenosine metabolism in human blood. Eur J
Pharmacol 93:21-26
Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, Tanino M, Takamura K, Nagai K,
Hosokawa T, Nishimura M (2004) Effect of low-dose theophylline on airway inflammation in
COPD. Respirology 9:249-254
Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E,
Gresser M, Huang Z (2000) Conformational difference between PDE4 apoenzyme and holo-
enzyme. Biochemistry 39:6449-6458
Laliberte F, Liu S, Gorseth E, Bobechko B, Bartlett A, Lario P, Gresser MJ, Huang Z (2002) In
vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett 512:205-208
Li X, Baillie GS, Houslay MD (2009) Mdm2 directs the ubiquitination of
b
arrestin-sequestered
cAMP phosphodiesterase-4D5. J Biol Chem 284:16170-16182
Lim J, Pahlke G, Conti M (1999) Activation of the cAMP-specific phosphodiesterase PDE4D3 by
phosphorylation.
Identification and function of an inhibitory domain. J Biol Chem
274:19677-19685
Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK,
Menniti FS (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9.
Proc Natl Acad Sci USA 105:13309-13314
Livi GP, Kmetz P, McHale MM, Cieslinski LB, Sathe GM, Taylor DP, Davis RL, Torphy TJ,
Balcarek JM (1990) Cloning and expression of cDNA for a human low-Km, rolipram- sensitive
cyclic AMP phosphodiesterase. Mol Cell Biol 10:2678-2686
Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F (2010) Cardiac hypertrophy is
not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl
Acad Sci USA 107:5646-5651
Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay
MD (2005) RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phospho-
diesterase Interacting with {beta}Arrestin to Control the Protein Kinase A/AKAP79-mediated
Switching of the {beta}2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells.
J Biol Chem 280:33178-33189
MacFarland RT, Zelus BD, Beavo JA (1991) High concentrations of a cGMP-stimulated phos-
phodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glo-
merulosa cells. J Biol Chem 266:136-142
Martinez SE, Beavo JA, Hol WG (2002a) GAF domains: two billion year old molecular switches
that bind cyclic nucleotides. Mol Interv 2:317-323
